Aspira Women's Health Inc.
AWHL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AWHL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AWHL
Aspira Women's Health Inc. (AWHL) is a diagnostics company focused on women's health, offering a suite of tests for ovarian cancer risk assessment and endometriosis, but faces significant financial distress with minimal cash, negative equity, and a going concern warning.
Key risk: Going concern risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Aspira Women's Health Inc..
Aspira Women's Health Inc. (AWHL) is a diagnostics company focused on women's health, offering a suite of tests for ovarian cancer risk assessment and endometriosis, but faces significant financial distress with minimal cash, negative equity, and a going concern warning.
- Cash and cash equivalents were $0.5M as of 2026-06-30, with a working capital deficit of $2.5M and shareholders' equity of -$6.9M [sec_mda · as of 2026-08-14].
- Net loss for the six months ended June 30, 2026 was $2.4M, with no revenue reported for that period [sec_mda · as of 2026-08-14].
- The company has an accumulated deficit of $544.2M as of December 31, 2025 [sec_mda · as of 2026-04-01].
- Aspira markets diagnostic tests including Ova1, Overa, Ova1Plus, OvaWatch, ENDOinform, and OVAinform, as well as the Aspira Synergy platform [sec_mda · as of 2026-05-15].
- There is substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-04-01].
What works
- The company has a portfolio of proprietary diagnostic tests for ovarian cancer and endometriosis, including Ova1, Overa, Ova1Plus, OvaWatch, ENDOinform, and OVAinform, which may address unmet needs in women's health [sec_mda · as of 2026-05-15].
- Management expects revenue from Aspira Labs' products to be the only material, recurring source of cash for the remainder of 2026, indicating a focused commercial strategy [sec_mda · as of 2026-08-14].
- The company is investing in its product pipeline, with research and development expenses expected to increase modestly in the second quarter of 2026 [sec_mda · as of 2026-05-15].
What to weigh
- The company has a working capital deficit of $2.5M as of June 30, 2026, and negative shareholders' equity of -$6.9M, indicating severe liquidity constraints [sec_mda · as of 2026-08-14].
- There is substantial doubt about the company's ability to continue as a going concern, which could adversely affect stock price and capital-raising ability [sec_mda · as of 2026-04-01].
- The company has an accumulated deficit of $544.2M as of December 31, 2025, and expects to incur net losses and negative cash flows from operations in 2026 [sec_mda · as of 2026-04-01].
- Revenue from products is uncertain, with no assurance of generating substantial revenues or cash flows from Aspira Labs' operations [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Cash position and working capital deficit as of June 30, 2026
“As of June 30, 2026, we had $477,000 in cash and cash equivalents, $5,338,000 in current liabilities, and a working capital deficit of $2,542,000.”
SEC MD&A · August 14, 2026
Going concern warning
“There is substantial doubt about our ability to continue as a going concern, and this may adversely affect our stock price and our ability to raise capital.”
SEC MD&A · April 1, 2026
Accumulated deficit as of December 31, 2025
“We have incurred significant losses and negative cash flows from operations since inception and have an accumulated deficit of $544,177,000 as of December 31, 2025.”
SEC MD&A · April 1, 2026
Product portfolio includes Ova1, Overa, Ova1Plus, OvaWatch, ENDOinform, OVAinform, and Aspira Synergy
“expected market adoption of our current and prospective diagnostic tests, including Ova1, Overa, Ova1Plus, OvaWatch, ENDOinform and OVAinform, as well as our Aspira Synergy platform”
SEC MD&A · May 15, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern due to limited cash and recurring losses [sec_mda · as of 2026-04-01].
- Liquidity and capital constraints — Working capital deficit of $2.5M and negative equity of -$6.9M as of June 30, 2026, limiting operational flexibility [sec_mda · as of 2026-08-14].
- Revenue uncertainty — No assurance of generating substantial revenues or cash flows from product sales; revenue is the only material cash source [sec_mda · as of 2026-08-14].
- Accumulated losses — Accumulated deficit of $544.2M as of December 31, 2025, with expected continued net losses [sec_mda · as of 2026-04-01].
What to watch
- Ability to raise additional capital or secure financing to address the working capital deficit and going concern status [sec_mda · as of 2026-08-14].
- Revenue growth from Aspira Labs' product sales, particularly OvaSuite tests, as the primary cash source for the remainder of 2026 [sec_mda · as of 2026-08-14].
- Progress in research and development pipeline, including clinical studies and new product launches, which may impact future cash needs [sec_mda · as of 2026-05-15].
- Market adoption rates of diagnostic tests such as Ova1, Overa, OvaWatch, and ENDOinform [sec_mda · as of 2026-05-15].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Aspira Women's Health Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aspira Women's Health Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
1.8 months
OCF -$2M · Net income -$2M
Lead: Approved
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 0.8%
- Days to cover
- 0.0
- Shares short
- 252,929
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AWHL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aspira Women's Health Inc.?
Aspira Women's Health Inc. (AWHL) is a diagnostics company focused on women's health, offering a suite of tests for ovarian cancer risk assessment and endometriosis, but faces significant financial distress with minimal cash, negative equity, and a going concern warning.
What is Aspira Women's Health Inc.'s lead drug candidate?
Aspira Women's Health Inc.'s most advanced tracked candidate is ova1 (Approved) for likelihood of malignancy in women with an ovarian adnexal mass.
Who is the CEO of Aspira Women's Health Inc.?
Mr. Michael Buhle is the chief executive officer of Aspira Women's Health Inc. (AWHL).
Where is Aspira Women's Health Inc. headquartered?
Aspira Women's Health Inc. (AWHL) is headquartered in Austin, TX, United States.
What therapeutic areas does Aspira Women's Health Inc. focus on?
Aspira Women's Health Inc. develops therapies across Oncology, Pain, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.